Loading provider…
Loading provider…
Hematology & Oncology Physician in Jacksonville, FL
NPI: 1215926944Primary Practice Location
MAYO CLINIC
4500 San Pablo Rd S, Jacksonville, FL
Primary Employer
Mayo Clinic Jacksonville
mayoclinic.org
HQ Phone
Get MD Vivek's Phone Numberphone_androidMobile
Get MD Vivek's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
AZ State Medical License
2000
FL State Medical License
2001 - 2027
MN State Medical License
1994 - 2026
OK State Medical License
1996 - 2005

American Board of Internal Medicine
Hematology
University of Minnesota
Fellowship • Hematology and Medical Oncology
1993 - 1996
UMass Chan Medical School
umassmed.edu
Residency • Internal Medicine
1991 - 1993
All India Institute of Medical Sciences
Medical School
Until 1980
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 96413Infusion of chemotherapy into a vein up to 1 hour | 254 | 302 |
| 2 | 96375Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 193 | 494 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 144 | 271 |
| 4 | 36591Collection of blood specimen from a completely implantable venous access device | 137 | 166 |
| 5 | J2405Injection, ondansetron hydrochloride, per 1 mg | 134 | 1,476 |
Authors: Srilekha Bodepudi, Mays Abdulazeez, Taimur Sher, Shahrukh Hashmi, Nandita Khera, Sikander Ailawadhi, Abhisek Swaika, Meghna Ailawadhi, Pooja Advani, Asher Chanan-Khan
Journal: J Oncol Pharm Pract
Publication Date: 2021-03-09
Lead Sponsor: K36 Therapeutics, Inc.
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: DRUG: Cohort A1 & A2: KTX-1001, DRUG: Cohort B1 & B2: KTX-1001+Mezigdomide, DRUG: Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), DRUG: Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Lead Sponsor: Takeda
Intervention / Treatment: DRUG: Daratumumab and Hyaluronidase-fihj, DRUG: TAK-981, DRUG: Mezagitamab
Lead Sponsor: Mayo Clinic
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, DRUG: Ixazomib Citrate, DRUG: Dexamethasone, DRUG: Cyclophosphamide, BIOLOGICAL: Daratumumab